Literature DB >> 8112191

Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity.

G Ruotolo1, M Parlavecchia, M R Taskinen, G Galimberti, A Zoppo, N A Le, F Ragogna, P Micossi, G Pozza.   

Abstract

OBJECTIVE: To characterize the effects of intraperitoneal insulin pump therapy on lipoprotein composition and lipolytic enzyme activity in patients with insulin-dependent diabetes mellitus (IDDM). RESEARCH DESIGN AND METHODS: Ten IDDM patients were studied 3 times: when receiving conventional subcutaneous insulin therapy and at 3 and 9 months from the initiation of intraperitoneal insulin regimen. Ten nondiabetic subjects matched for age, sex, and body weight were studied as controls. Levels of cholesterol, triglycerides, apolipoprotein A-I (apoA-I) and B (apoB) were measured in total plasma and lipoprotein fractions (very-low-density lipoprotein [VLDL], intermediate-density lipoprotein [IDL], low-density lipoprotein [LDL], and high-density lipoprotein [HDL]: HDL2 and HDL3). Postheparin plasma lipoprotein lipase and hepatic lipase activities were determined by an immunochemical method.
RESULTS: IDDM patients showed higher levels of HDL3 and lower levels of HDL2 particles during intraperitoneal insulin therapy in comparison with subcutaneous insulin therapy. Both cholesterol and apoA-I significantly increased in HDL3 and decreased in HDL2 during intraperitoneal treatment. Plasma total cholesterol significantly decreased in the diabetic patients at 3 months of intraperitoneal insulin therapy compared with both subcutaneous insulin regimen and control subjects. IDL triglyceride concentrations during intraperitoneal treatment were significantly lower than those seen with subcutaneous therapy. Furthermore, triglyceride:apoB ratio in VLDL and cholesterol:apoB ratio in LDL significantly decreased in IDDM patients treated by intraperitoneal insulin. A significant increase in the activity of hepatic lipase with intraperitoneal insulin therapy by 9 months compared with subcutaneous insulin therapy has been shown.
CONCLUSIONS: The increased activity of hepatic lipase after intraperitoneal insulin administration in IDDM patients appears to be one of the main determinants of lipoprotein changes observed, resulting in the normalization of lipoprotein composition during this mode of therapy. The normal inverse relationship between VLDL triglycerides and HDL cholesterol, which was not present in IDDM patients with subcutaneous therapy, was restored with intraperitoneal insulin regimen.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8112191     DOI: 10.2337/diacare.17.1.6

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  11 in total

1.  Effect of thyroid hormone binding proteins on insulin receptor binding of B1-thyronine-insulin analogues.

Authors:  Fariba Shojaee-Moradie; Michelle P Y Chan; Micayla A Telfer; Dietrich Brandenburg; Erik Sundermann; Heike Eckey; Jens Kleinjung; Achim Schüttler; Richard H Jones
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

2.  Reference distributions for apolipoproteins AI and B and B/AI ratios: comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Thomas B Ledue; Santica Marcovina; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

3.  A New Optimized Percutaneous Access System for CIPII.

Authors:  Rosa Garcia-Verdugo; Michael Erbach; Oliver Schnell
Journal:  J Diabetes Sci Technol       Date:  2017-03-01

Review 4.  Cardiovascular risk in double diabetes mellitus--when two worlds collide.

Authors:  Stephen J Cleland
Journal:  Nat Rev Endocrinol       Date:  2012-04-10       Impact factor: 43.330

5.  Normal metabolism of apolipoprotein B100-containing lipoproteins despite qualitative abnormalities in type 1 diabetic men.

Authors:  L Duvillard; E Florentin; M L Lalanne-Mistrich; J M Petit; S Baillot-Rudoni; A Brun-Pacaud; J M Brun; P Gambert; B Vergès
Journal:  Diabetologia       Date:  2005-05-26       Impact factor: 10.122

Review 6.  Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?

Authors:  S J Cleland; B M Fisher; H M Colhoun; N Sattar; J R Petrie
Journal:  Diabetologia       Date:  2013-04-24       Impact factor: 10.122

7.  Very low density lipoprotein subfraction abnormalities in IDDM patients: any effect of blood glucose control?

Authors:  L Patti; L Di Marino; A Maffettone; G Romano; G Annuzzi; G Riccardi; A A Rivellese
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

8.  Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol.

Authors:  Tsutomu Hirano; Rieko Kodera; Takeshi Hirashima; Natsuko Suzuki; Ema Aoki; Mitsuru Hosoya; Taito Oshima; Toshiyuki Hayashi; Shinji Koba; Motoko Ohta; Noriyuki Satoh; Yasuki Ito
Journal:  J Atheroscler Thromb       Date:  2021-04-29       Impact factor: 4.394

Review 9.  Pathophysiology of diabetic dyslipidaemia: where are we?

Authors:  Bruno Vergès
Journal:  Diabetologia       Date:  2015-03-01       Impact factor: 10.122

10.  The Proline 7 Substitution in the Preproneuropeptide Y Is Associated with Higher Hepatic Lipase Activity In Vivo.

Authors:  Stephan Schiekofer; Marcus E Kleber; Winfried Maerz; Franz M Rasche; Jochen G Schneider
Journal:  Int J Endocrinol       Date:  2017-05-30       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.